title: A leukemic stem cell with intrinsic drug efflux capacity in acute myeloid leukemia.
abstract: The hematopoietic stem cell underlying acute myeloid leukemia (AML) is controversial. Flow cytometry and the DNA-binding dye Hoechst 33342 were previously used to identify a distinct subset of murine hematopoietic stem cells, termed the side population (SP), which rapidly expels Hoechst dye and can reconstitute the bone marrow of lethally irradiated mice. Here, the prevalence and pathogenic role of SP cells in human AML were investigated. Such cells were found in the bone marrow of more than 80% of 61 patients and had a predominant CD34(low/-) immunophenotype. Importantly, they carried cytogenetic markers of AML in all 11 cases of active disease examined and in 2 out of 5 cases in complete hematological remission. Comparison of daunorubicin and mitoxantrone fluorescence emission profiles revealed significantly higher drug efflux from leukemic SP cells than from non-SP cells. Three of 28 SP cell transplants generated overt AML-like disease in nonobese diabetic--severe combined immunodeficient mice. Low but persistent numbers of leukemic SP cells were detected by molecular and immunological assays in half of the remaining mice. Taken together, these findings indicate that SP cells are frequently involved in human AML and may be a target for leukemic transformation. They also suggest a mechanism by which SP cells could escape the effects of cytostatic drugs and might eventually contribute to leukemia relapse. (Blood. 2001;98:1166-1173)
authors.affiliation: Center for Cell and Gene Therapy, Baylor College of Medicine, Houston, TX 77030, USA.
authors.forename: G G
authors.initials: GG
authors.lastname: Wulf
authors.forename: R Y
authors.initials: RY
authors.lastname: Wang
authors.forename: I
authors.initials: I
authors.lastname: Kuehnle
authors.forename: D
authors.initials: D
authors.lastname: Weidner
authors.forename: F
authors.initials: F
authors.lastname: Marini
authors.forename: M K
authors.initials: MK
authors.lastname: Brenner
authors.forename: M
authors.initials: M
authors.lastname: Andreeff
authors.forename: M A
authors.initials: MA
authors.lastname: Goodell
mesh_terms: D000208:Acute Disease; D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000818:Animals; D000903:Antibiotics, Antineoplastic / Q000493:pharmacokinetics; D000970:Antineoplastic Agents / Q000493:pharmacokinetics; D001562:Benzimidazoles / Q000493:pharmacokinetics; D002469:Cell Separation; D002648:Child; D002675:Child, Preschool; D003630:Daunorubicin / Q000493:pharmacokinetics; D004351:Drug Resistance; D005260:Female; D006801:Humans; D016130:Immunophenotyping; D007223:Infant; D007951:Leukemia, Myeloid / Q000188:drug therapy / Q000473:pathology*; D007963:Leukocytes, Mononuclear; D008297:Male; D051379:Mice; D016688:Mice, Inbred NOD; D008875:Middle Aged; D008942:Mitoxantrone / Q000493:pharmacokinetics; D009190:Myelodysplastic Syndromes / Q000188:drug therapy / Q000473:pathology; D009368:Neoplasm Transplantation; D016609:Neoplasms, Second Primary; D033581:Stem Cell Transplantation; D013234:Stem Cells / Q000187:drug effects / Q000473:pathology*; D014407:Tumor Cells, Cultured / Q000187:drug effects / Q000637:transplantation
chemical_list: D000903:Antibiotics, Antineoplastic; D000970:Antineoplastic Agents; D001562:Benzimidazoles; D008942:Mitoxantrone; C017807:bisbenzimide ethoxide trihydrochloride; D003630:Daunorubicin